Del Labs
This article was originally published in The Tan Sheet
Executive Summary
Second quarter sales increased 8.7% to $76.7 mil. and net earnings grew 21.6% to $1.9 mil. Del's subsidiary, Del Pharmaceuticals, markets Orajel oral analgesics, Arthricare, Pronto, Tanac, Propa pH and the new Dermarest Psoriasis products. The OTC business reported a year-to-year increase in sales and income, according to the company. Del's sales for the first six months grew 8.9% to $144.1 mil. and earnings jumped 24.5% to $2.4 mil